Literature DB >> 30798636

Emerging role of nanomedicine in the treatment of neuropathic pain.

Pankaj Bidve1, Namrata Prajapati1, Kiran Kalia1, Rakesh Tekade2, Vinod Tiwari1.   

Abstract

Neuropathic pain (NeP) is a complex chronic pain condition associated with nerve injury. Approximately, 7-10% of the general population across the globe is suffering from this traumatic condition, but the existing treatment strategies are inadequate to deliver pain relief and are associated with severe adverse effects. To overcome these limitations, lot of research is focussed on developing new molecules with high potency and fewer side effects, novel cell and gene-based therapies and modification of the previously approved drugs by different formulation aspects. Nanomedicine has attracted a lot of attention in the treatment of many diverse pathological conditions because of their unique physiochemical and biological properties. In this manuscript, we highlighted the emerging role of nanomedicine in different therapies (drug, cell and gene), also we emphasised on the challenges associated with nanomedicine such as development of well-characterised nanoformulation, scaling of batches with reproducible results and toxicity along with this we discussed about the future of nanomedicine in the treatment of neuropathic pain.

Entities:  

Keywords:  Neuropathic pain; challenges; drug therapy; gene therapy; nanomedicine

Mesh:

Substances:

Year:  2019        PMID: 30798636     DOI: 10.1080/1061186X.2019.1587444

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  55 in total

1.  Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements.

Authors:  Francisco J M Mojica; César Díez-Villaseñor; Jesús García-Martínez; Elena Soria
Journal:  J Mol Evol       Date:  2005-02       Impact factor: 2.395

2.  CRISPR provides acquired resistance against viruses in prokaryotes.

Authors:  Rodolphe Barrangou; Christophe Fremaux; Hélène Deveau; Melissa Richards; Patrick Boyaval; Sylvain Moineau; Dennis A Romero; Philippe Horvath
Journal:  Science       Date:  2007-03-23       Impact factor: 47.728

3.  Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components.

Authors:  Keith Pardee; Alexander A Green; Melissa K Takahashi; Dana Braff; Guillaume Lambert; Jeong Wook Lee; Tom Ferrante; Duo Ma; Nina Donghia; Melina Fan; Nichole M Daringer; Irene Bosch; Dawn M Dudley; David H O'Connor; Lee Gehrke; James J Collins
Journal:  Cell       Date:  2016-05-06       Impact factor: 41.582

4.  Functionally diverse type V CRISPR-Cas systems.

Authors:  Winston X Yan; Pratyusha Hunnewell; Lauren E Alfonse; Jason M Carte; Elise Keston-Smith; Shanmugapriya Sothiselvam; Anthony J Garrity; Shaorong Chong; Kira S Makarova; Eugene V Koonin; David R Cheng; David A Scott
Journal:  Science       Date:  2018-12-06       Impact factor: 47.728

5.  Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.

Authors:  Aaron A Smargon; David B T Cox; Neena K Pyzocha; Kaijie Zheng; Ian M Slaymaker; Jonathan S Gootenberg; Omar A Abudayyeh; Patrick Essletzbichler; Sergey Shmakov; Kira S Makarova; Eugene V Koonin; Feng Zhang
Journal:  Mol Cell       Date:  2017-01-05       Impact factor: 17.970

6.  C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.

Authors:  Omar O Abudayyeh; Jonathan S Gootenberg; Silvana Konermann; Julia Joung; Ian M Slaymaker; David B T Cox; Sergey Shmakov; Kira S Makarova; Ekaterina Semenova; Leonid Minakhin; Konstantin Severinov; Aviv Regev; Eric S Lander; Eugene V Koonin; Feng Zhang
Journal:  Science       Date:  2016-06-02       Impact factor: 47.728

7.  New CRISPR-Cas systems from uncultivated microbes.

Authors:  David Burstein; Lucas B Harrington; Steven C Strutt; Alexander J Probst; Karthik Anantharaman; Brian C Thomas; Jennifer A Doudna; Jillian F Banfield
Journal:  Nature       Date:  2016-12-22       Impact factor: 49.962

8.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

9.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

10.  CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.

Authors:  Janice S Chen; Enbo Ma; Lucas B Harrington; Maria Da Costa; Xinran Tian; Joel M Palefsky; Jennifer A Doudna
Journal:  Science       Date:  2018-02-15       Impact factor: 47.728

View more
  1 in total

Review 1.  Novel Therapies for the Treatment of Neuropathic Pain: Potential and Pitfalls.

Authors:  Pottathil Shinu; Mohamed A Morsy; Anroop B Nair; Abdulaziz K Al Mouslem; Katharigatta N Venugopala; Manoj Goyal; Monika Bansal; Shery Jacob; Pran Kishore Deb
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.